Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
JNJ · NYSE · Pharmaceuticals
Johnson & Johnson (JNJ) · oqro.io/stocks/JNJ · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$272.70−6.00 (−2.15%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
No open-market purchase by an insider of Johnson & Johnson was filed in the last 90 days. The latest on record was on Dec 1, 2025.
Since 2006, Johnson & Johnson insiders reported 25 open-market purchases and 433 sales on Forms 4 and 5, with purchases in 13 different years, most recently 2025.
In the last 90 days, 2 insiders of Johnson & Johnson (JNJ) reported 3 open-market sales worth $12.9M in total on SEC Form 4. The largest seller by value was Timothy Schmid, with $9.23M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Yes. Members of Congress disclosed 26 trades in Johnson & Johnson (JNJ) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Rep. Thomas H. Kean Jr. (NJ07), Rep. Lloyd Doggett (TX37), Sen. John Boozman and 5 other members.
Johnson & Johnson's next results are expected on Jan 26, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+36.3% (+$72.70) from Nov 18, 2025 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $200.00 on Nov 18, 2025 to $272.70 on Nov 18, 2026 (+36.3%). Disclosed in this range: 30 insider trades, 0 pre-arranged insider sales, 19 Congress trades, and 466 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Medicines and medical devices.
Last 12 months
+36.4%
Market value
$656B
S&P 500 +10.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 17.1M shares sold short (0.7% of shares outstanding), +1.8% vs the previous count, 2.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Johnson & Johnson: 1 fund cut or exited a position in the latest available 13F filings and 1 member of Congress disclosed sales. 2 of 3 tracked groups show selling activity. Based on public disclosures; it does not say why, or what happens next. Our test of this pattern
Revenue
$25.4B
+5.9% vs the same quarter a year earlier
Free cash flow, last 12 months
$20.6B
This quarter $6.36B, a year earlier $8.01B
Net debt
$18.9B
Debt $35.8B, cash $16.9B, at Sep 27, 2026
Net income, last 12 months
$16.1B
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 13, 2026.
Revenue, fiscal 2025
$94.2B
+6.0% vs the year before
Net income, fiscal 2025
$26.8B
As reported in the annual filing
Shares outstanding
2.41B
As of Oct 15, 2026
In fiscal 2025 the company spent $5.95B buying back its own shares. Cash actually paid, from its cash-flow statement.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Insider selling
Traded Nov 12 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade −3.8% · S&P 500 −3.6% · to Nov 18
Johnson & Johnson's Chief Legal Officer sold $3.72M of Johnson & Johnson shares. The filing does not indicate a pre-arranged trading plan.
Federal contracts
Emergency pharmacy carvykti for RMR
The Department of Veterans Affairs has committed $385K to Johnson & Johnson so far. It runs until Dec 31, 2026.
Congress
Traded Sep 30 · disclosed 30 days laterSits on House Energy and Commerce
Since the trade +3.0% · S&P 500 −4.3% · to Nov 18
4 different filers disclosed JNJ within 90 days.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Against the S&P 500 over the year
Since Nov 17, 2025, JNJ is up 36.6% and the index fund is up 9.7%: 27 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much JNJ moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
On the public record for Johnson & Johnson over the 12 months to Nov 19, 2026: 92 FDA records (5th most among listed companies), 1 executive contribution and 2 clinical trials.
Insiders of Johnson & Johnson reported 25 open-market purchases and 433 sales since 2006; purchases in 13 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $154M29×29 trades |
| 2025 | $258K1×1 trade | $46.1M8×8 trades |
| 2024 | $147K1×1 trade | $11.7M3×3 trades |
| 2023 | — | $8.09M4×4 trades |
| 2022 | — | $82.1M199×199 trades |
| 2021 | — | $816K1×1 trade |
| 2020 | $64K1×1 trade | $29.6M6×6 trades |
| 2019 | $1.13M2×2 trades | $285K1×1 trade |
| 2018 | $503K3×3 trades | $100M10×10 trades |
| 2017 | — | $39.9M7×7 trades |
| 2016 | $100K1×1 trade | $36M8×8 trades |
| 2015 | $496K2×2 trades | $35.2M5×5 trades |
| 2014 | — | $8.35M6×6 trades |
| 2013 | — | $10.4M6×6 trades |
| 2012 | — | $57.3M9×9 trades |
| 2011 | $252K4×4 trades | $52.7M9×9 trades |
| 2010 | $187K3×3 trades | $33.3M12×12 trades |
| 2009 | $172K2×2 trades | $27.7M14×14 trades |
| 2008 | $247K3×3 trades | $11.6M34×34 trades |
| 2007 | $334K1×1 trade | $9.48M28×28 trades |
| 2006 | $290K1×1 trade | $29.7M34×34 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
1 active phase 3 trial and 1 active phase 2 trial led by this company, mostly in carcinoma, squamous cell, carcinoma, non-small-cell lung. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Last results
Oct 13, 2026
More than 30 days ago
Next results, expected
Jan 26, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Johnson & Johnson's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Johnson & Johnson's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
30 certified in FY2026 Q3, vs 14 a year earlier. 30 positions in total, median offered wage $169K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Short sale volume: 32.3% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 45.2%. FINRA daily files, to Nov 18, 2026.
Fails to deliver: 4,619 shares (about $1.22M) were not delivered on time for settlement on Oct 26, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
44 approvals or clearances and 50 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.